Mantle Cell Lymphoma Presenting as a Primary Cutaneous Mass: A Case Report
DOI:
https://doi.org/10.2340/actadv.v105.adv-2025-0015Keywords:
mantle cell carcinomaDownloads
References
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid Neoplasms. Leukemia 2022; 36: 1720–1748. DOI: https://doi.org/10.1038/s41375-022-01620-2
Jain P, Wang ML. Mantle cell lymphoma in 2022 – A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 2022; 97: 638–656. DOI: https://doi.org/10.1002/ajh.26523
Akay BN, Farabi B, Atak MF, Kuzu I, Heper AO. Cutaneous involvement of mantle cell lymphoma: report of two cases with dermatoscopic features. Dermatol Pract Concept 2022; 12: e2022064. DOI: https://doi.org/10.5826/dpc.1202a64
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, et al. NCCN guidelines® insights: B-cell lymphomas, version 6.2023. J Natl Compr Canc Netw 2023; 21: 1118–1131. DOI: https://doi.org/10.6004/jnccn.2023.0057
Trutzer IM, Lossos IS. Relapsed mantle cell lymphoma manifesting with soft tissue tumors of the extremities: University of Miami experience and review of the literature. Ann Hematol 2024; 103: 4581–4588. DOI: https://doi.org/10.1007/s00277-024-05997-1
Li S, Tang G, Jain P, Lin P, Xu J, Miranda RN, et al. SOX11+ large B-cell neoplasms: cyclin D1-negative blastoid/pleomorphic mantle cell lymphoma or large B-cell lymphoma? Mod Pathol 2024; 37: 100405. DOI: https://doi.org/10.1016/j.modpat.2023.100405
Scheubeck G, Jiang L, Hermine O, Kluin-Nelemans HC, Schmidt C, Unterhalt M, et al. Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia 2023; 37: 1887–1894. DOI: https://doi.org/10.1038/s41375-023-01977-y
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022; 386: 2482–2494. DOI: https://doi.org/10.1056/NEJMoa2201817
Dreyling M, Doorduijn JK, Giné E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation in previously untreated mantle cell lymphoma (TRIANGLE). Lancet 2024; 403: 2293–2306. DOI: https://doi.org/10.1016/S0140-6736(24)00184-3
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood 2022; 139: 3148–3158. DOI: https://doi.org/10.1182/blood.2021014162
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
